top.gif - 25.77 K

Smoking Marijuana:
Safety Study Completed

By John S. James
AIDS Treatment News

potleaf.gif - 4.72 K After years of bureaucratic nightmare, a research team at the University of California has completed a safety study of smoked marijuana vs. oral dronabinol (Marinol(R), an FDA- approved oral drug with the same main active ingredient as marijuana) vs. placebo in HIV/AIDS patients being treated with an antiviral regimen including a protease inhibitor (either indinavir or nelfinavir).

The main purpose of the study was to find out whether cannabinoids, the active ingredient in marijuana, could raise the viral load by interacting either with the antiretrovirals, or with the immune system. No such problem was found.(1)

All three study arms (marijuana, dronabinol, and placebo) gained weight--not surprisingly as the study was conducted while volunteers remained 24 hours a day in a hospital research facility, and were probably less active than they would have been outside.

But those in the marijuana and dronabinol arms gained more (3.51 kg and 3.18 kg, vs. 1.30 kg for the placebo arm). Again this is not surprising, as marijuana is often used as an appetite stimulant.

This study randomly assigned 67 patients to marijuana, dronabinol, or an oral placebo (the smoked marijuana arm was not blinded, probably because of the difficulty of providing a smoked placebo); interestingly, half of the placebo recipients thought they were getting dronabinol, and about a quarter of the dronabinol recipients thought they were getting placebo.

Two volunteers in the marijuana arm and one in the dronabinol arm reported neuropsychiatric symptoms; two of these three (one in each arm) chose to leave the study as a result. (All of the volunteers were previously experienced with marijuana--and were required not to have used it for 30 days before entry to the study.)

Note: In the poster printed quickly for distribution at the Durban conference, two minus signs were mistakenly omitted in reporting viral loads; viral load went down slightly in both the marijuana and the dronabinol group, and up slightly with the placebo. However, none of these changes was large enough to be statistically significant.

Related Articles from the GayToday Archive:
Medical Marijuana: New Treatement Uses, Old Government Abuses

Drug Interactions for Patients and Professionals

Poppers: Increase Risk of Cancer, Immune Disorder

Related Sites:
AIDS Treatment News

Marijuana As a Medicine
GayToday does not endorse related sites.


This trial had to be designed to look at safety instead of efficacy, because the Federal government must give special permission for any marijuana study, and provide the drug as well.

It has clearly been Federal policy to only allow studies that look for possible problems with marijuana, so that the study will either find something negative, or find nothing; studies testing for medical benefit have not yet been allowed, so that no information favorable to marijuana could come into existence.

In this case, the standard body weight measurement used in safety studies found a benefit. (Weight gain would be regarded as a benefit here, as marijuana is often used medically by patients who need to eat more and gain weight, not by those who are trying to lose weight.)

This study was presented as a late-breaker poster at the Durban conference; the summary noted that "future trials should investigate the effectiveness of marijuana in: appetite stimulation/weight gain nausea [and] pain."

If such a study is allowed to be done, we would suggest adding a fourth arm--to compare placebo, vs. marijuana, vs. dronabinol, vs. choice (of either marijuana, dronabinol, or neither, allowing switching whenever the volunteers wanted).

Clearly some patients do better with smoked marijuana, and others with oral dronabinol; so we suspect that for some individuals there could be large differences in effectiveness in different directions, which would tend to balance each other out, and could result in little difference for the group average.

If this is the case, then a patients' choice among the drugs could well be more safe and/or effective (for many individuals, and also for the group average) than assignment to either drug alone.
AIDS Treatment News Published twice monthly

Subscription and Editorial Office: P.O. Box 411256
San Francisco, CA 94141
800/TREAT-1-2 toll-free U.S. and Canada
415/255-0588 regular office number
Fax: 415/255-4659

Editor and Publisher: John S. James
Associate Editor: Tadd T. Tobias
Reader Services: Tom Fontaine and Denny Smith
Operations Manager: Danalan Richard Copeland

Statement of Purpose: AIDS Treatment News reports on experimental and standard treatments, especially those available now. We interview physicians, scientists, other health professionals, and persons with AIDS or HIV; we also collect information from meetings and conferences, medical journals, and computer databases. Long-term survivors have usually tried many different treatments, and found combinations which work for them. AIDS Treatment News does not recommend particular therapies, but seeks to increase the options available.

Subscription Information: Call 800/TREAT-1-2 Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks.

ISSN # 1052-4207

Copyright 2000 by John S. James.

bannerbot.gif - 8.68 K
© 1997-2000 BEI